Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: December 2012
Date of Filing: December 07, 2012
This filing serves as a notification of the publication of a Supplementary Prospectus dated December 5, 2012. The document supplements a Base Prospectus dated September 5, 2012, regarding GSK's £15,000,000,000 Euro Medium Term Note Programme. The prospectus has been approved by the UK Listing Authority.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing regarding a debt issuance programme rather than a financial results report.
Material Changes
No material changes to financial performance or operations are reported in this specific filing. The primary update is the availability of the Supplementary Prospectus for the Euro Medium Term Note Programme.
Guidance, Outlook, and Risks
Access Restrictions: The filing explicitly states that the information in the Supplementary and Base Prospectuses may be targeted at residents of specific countries only. It is not intended for use by persons outside these jurisdictions.
Availability: The prospectus is available via the National Storage Mechanism (NSM) and on GSK's corporate website.
Management Commentary: No management commentary, guidance, or outlook regarding future financial performance is included in this text.
Investor Verification Checklist
- Verify the specific terms and conditions of the £15 billion Euro Medium Term Note Programme in the full Supplementary Prospectus.
- Confirm eligibility to access the prospectus based on country of residence as defined in the Base Prospectus.
- Review the full Base Prospectus dated September 5, 2012, for comprehensive risk factors and financial data not included in this summary.
- Check the National Storage Mechanism (NSM) or GSK's official reports page for the latest version of the documents.